The construction and immune efficacy of recombinant Lactobacillus casei strains expressing VP3 from goose parvovirus

• Published in: Veterinarski arhiv Vol. 94; no. 4; pp. 323 - 338
• Main Authors: Chen, Yan-Hui, Pei, Yi-Feng, Yu, Qian, Dong, Hao, Jin, Li-Bo
• Format: Journal Article
• Language: English
• Published: Sveuciliste U Zagrebu 01-07-2024
• Subjects: B cells; Communicable diseases; Geese; Health aspects; Vaccines; China
• ISSN: 0372-5480; 1331-8055
• DOI: 10.24099/vet.arhiv.2461

Goose parvovirus (GPV) is a pathogen that causes Derzsy’s disease, which causes severe economic losses to China’s waterfowl breeding industry. The mortality rate of Derzsy’s disease reaches 90% in the 7 days. Lactobacillus casei (L. casei) is a common candidate vector in oral vaccines. It is widely used to prevent animal infectious diseases, parasites and tumors. L. casei is a promising vector for developing novel live bacterial vaccine vectors. In this study, L. casei was used as a presentation vector to construct a recombinant Lactobacillus casei expressing the VP3 gene of GPV, which was used as an oral vaccine to immunize goslings. and to evaluate its immunogenicity. In this study, we constructed recombinant Lactobacillus casei expressing the VP3 gene of goose parvovirus, and the immunogenicity and protective efficacy of Lc-pPG-612-VP3 were evaluated in SD rats and goslings. After oral immunization, Lc-pPG612-VP3 colonized the intestine for approximately 34 days and had good immunogenicity. The results showed that Lc-pPG-612-VP3 can induce humoral and mucosal immune responses in goslings, and enhance the transcriptional levels of cytokines in various tissues. The challenge experiment showed that the recombinant Lactobacillus casei had a certain preventive effect against Derzsy’s disease (30%), which was the same as the protection efficiency of the commercial vaccine.